2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Adverse Events, Biological Processes, Genomics, Hematopoiesis, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Bleeding and Clotting, Thrombocytopenias, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Aggressive Lymphoma, Research, AML, MDS, MPN, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2525 Durable disease control after allogeneic HCT following ivosidenib-based therapy despite frequent molecular persistence in IDH1-mutant AML

Vanessa E Kennedy, MD, Kuo-Kai Chin, MD2, Michael Walker3, Deedra Nicolet, MS4, Krzysztof Mrózek, MD, PhD5, Haley Roberts6, Jennifer Marvin-Peek, MD7, Yazan F. Madanat, MD8, Akriti G Jain, MD, FACP9, David Swoboda, MD10, Onyee Chan, MD11, Madelyn Burkart, MD12, Praneeth Baratam13, Yamuna Kondapally, MD14, Abhay Singh, MD, MPH15, Abdur Jabir, MD16, Najla Al Ali, MS17, Sarah Chen18, Ilias Oulidi Jerrar Oulidi, MD19, B. Douglas Smith, MD20, Daniel Pollyea, MD21, Ann-Kathrin Eisfeld, MD22, Alexander Joseph Ambinder, MD, MPH23
1 Stanford University, Stanford, California, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
4 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
5 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
6 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 UT Southwestern Medical Center, Dallas, Texas, United States
9 Taussig Cancer Center Cleveland Clinic, Cleveland, Ohio, United States
10 Tampa General Hospital Cancer Institute, Tampa, Florida, United States
11 Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, United States
12 Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
13 MUSC Hollings Cancer Center, Charleston, South Carolina, United States
14 Stanford University, Stanford, California, United States
15 Taussig Cancer Center Cleveland Clinic, Cleveland, Ohio, United States
16 University of Illinois College of Medicine, Chicago, Illinois, United States
17 Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, United States
18 University of South Florida College of Medicine, Tampa, Florida, United States
19 MUSC Hollings Cancer Center, Charleston, South Carolina, United States
20 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
21 University of Colorado, Aurora, Colorado, United States
22 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
23 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Background: Allogeneic hematopoietic cell transplantation (HCT) offers a potentially curative treatment for patients with acute myeloid leukemia (AML). Multiple therapies, including intensive chemotherapy and venetoclax-based regimens, have demonstrated the ability to achieve adequate pre-HCT disease control. IDH1 inhibitors, either as monotherapy or in combination with a hypomethylating agent (HMA), are an effective treatment for IDH1-mutated (IDH1mut) AML and have predominantly been studied in older or frailer adults. Their ability to provide a pathway to HCT is not well characterized. In this multicenter analysis, we describe the use of IDH1 inhibition as a bridge to HCT in the real-world setting.

Methods: From 8 institutions participating in the Myeloid Malignancy Association on Rapid Research Outcomes Working Group (MARROW) consortium, we identified 29 adults with IDH1mut AML who received the IDH inhibitor ivosidenib (Ivo) with or without HMA and subsequently proceeded to HCT. Primary outcomes included post-HCT non-relapse mortality (NRM), relapse-free survival (RFS), and overall survival (OS). 

Results: The median patient age was 68 (range, 27 - 78), 32% had an HCT-CI of ≥ 3, and 47% had adverse-risk disease by 2022 European LeukemiaNet criteria. The majority (n=18; 62%) received Ivo monotherapy while 11 patients (38%) received Ivo with an HMA. Twenty-one patients (72%) were treated in the frontline setting while 8 (28%) had relapsed/refractory (R/R) disease. There was no significant difference in patient age, HCT-CI, disease risk, or use of a concurrent HMA between patients treated in the frontline vs R/R setting.

 The number of Ivo ± HMA cycles prior to HCT varied considerably, with a median of 3 (range, 1 - 8).  All patients achieved remission prior to HCT, with 26 patients (90%) achieving complete remission (CR) and 3 (10%) CR with incomplete count recovery. Ten patients (34%) were measurable residual disease (MRD) positive as detected by flow cytometry (sensitivity threshold ≤1x10-4). Of the 22 patients who had repeat next-generation sequencing (NGS) prior to HCT, 19 (86.4%) had detectable IDH1 mutations with a median variant allele frequency of 10% (range, 3% - 48.7%). Detectable pre-HCT flow MRD and IDH1 mutations were frequently discordant. Of the 22 patients with both pre-HCT assays, 11 (50%) were discordant with detectable IDH1 mutation on NGS but negative flow, 8 (36%) were both positive, and 3 (14%) were both negative.  Across the full cohort, 14 patients (48%) received a related donor graft, 23 (82%) received reduced intensity conditioning, and 19 (68%) received post-transplant cyclophosphamide-based graft-vs-host disease (GVHD) prophylaxis. Ten of 29 patients (35%) resumed ivosidenib as maintenance therapy post-HCT.

 The median follow-up time post-HCT was 34.6 months. Following HCT, 100-day NRM was 0%, 2-year RFS was 78%, and 2-year OS was 78%. Although one-third of patients were MRD positive pre-HCT by flow cytometry, durable post-HCT flow MRD clearance was observed. Only 1 of 18 patients (5.5%), 1 of 12 (8.3%), and 1 of 13 (7.7%), remained flow MRD positive at day 100, 6 month, and 1-year post-HCT respectively.

 Interestingly, pre-HCT flow MRD status was not associated with post-HCT outcomes. The median RFS was 65.5 months in flow MRD-positive patients and 68.3 months in flow MRD-negative patients (p=.91), while median OS was 65.5 months and 68.3, respectively (p=.88). Patients treated with Ivo ± HMA in the frontline setting had a median RFS of 65.5 months, compared with 35.2 months among patients treated for R/R disease (p=.54),

Conclusions:  In patients with IDH1mut AML, ivosidenib with or without concurrent HMA, can achieve complete remissions and, for select patients, provides a pathway to potentially curative HCT. Durable post-HCT disease control was observed despite frequent pre-HCT molecular persistence. Following Ivo ± HMA, persistent IDH1 mutations are common and frequently discordant with flow cytometry-based MRD. These findings support the feasibility of Ivo-based therapy as a lower intensity pathway to HCT, while highlighting the need for larger studies to define the prognostic significance of IDH1 mutations before and after transplantation.

Vanessa E Kennedy, MD: BMS - Honoraria; Blueprint - Honoraria; Syndax - Honoraria; Rigel - Honoraria; Eurofins-Viracor - Research Funding; Menarini-Stemline - Consultancy (Includes expert testimony); Astellas - Consultancy (Includes expert testimony); Daiichi-Sankyo - Consultancy (Includes expert testimony); Arog - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony)